Meningioma

Early recognition of neurological symptoms due to a space-occupying lesion plays an important role in appropriate management. Thus, a comprehensive examination helps to identify cranial SP which can mimic another lesion such as meningioma.

Patient and family cancer history included other BAP1 -TPDS associated cancers, but only three patients had relatives with meningioma. Our findings indicate a need for routine craniospinal imaging in BAP1 -TPDS patients, and surveillance should include patients without family history of meningioma and patients under the age of 30.

P1, N=102, Recruiting, Jazz Pharmaceuticals | Trial primary completion date: Dec 2025 --> Jul 2026

P=N/A, N=210, Recruiting, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

P=N/A, N=21, Active, not recruiting, Massachusetts General Hospital | Trial primary completion date: Aug 2025 --> Aug 2027

This review comprehensively describes the physiological roles of TRAF7 and the pathophysiology of clinical conditions with TRAF7 alterations. We highlight important directions for future work to improve our understanding of the mechanisms underlying TRAF7 related disease, identify prognostic biomarkers that help guide clinical decision making, and potentially identify novel therapeutic targets to expand our treatment options for these patients.

Sintilimab failed to improve PFS-6 in both grade 1 and grade 2/3 recurrent/progressive meningiomas in this single-arm, single-center, and small-sample trial. When evaluating PD-1 inhibitor treatment for recurrent/progressive meningioma patients, who generally have a longer expected survival and high TMB, the use of the Immunotherapy Response Assessment in Neuro-Oncology (iRANO) criteria may be more appropriate to avoid overlooking potential clinical benefits.

The patient subsequently underwent chemotherapy with temozolomide and external beam radiation therapy with 60 Gy over 30 fractions...The patient was subsequently placed on bevacizumab...Additionally, there is difficulty in differentiating these tumors from meningiomas, with resultant misdiagnosis and management. It is critical to inform readers of its presence and emphasize the importance of its consideration in the differential diagnosis of dural-based tumors.

In this cohort, demographic, clinical, or radiological features did not reliably predict CDKN2A/B deletion. Several deletion-positive meningiomas were classified as grade 1 or 2, underscoring the disconnect between morphology and molecular grading. These findings support universal CDKN2A/B testing for accurate WHO classification and risk assessment.

Digital PR H-score assessment confirmed the inverse association between PR expression and WHO grade, as well as its correlation with proliferative activity. Using an FDA-cleared algorithm originally developed for breast carcinoma, this method provides objective and reproducible evaluation in meningiomas.

In this large cohort with extended follow-up, STR patients exhibited a second recurrence peak at 7 to 10 years postoperatively. Adjuvant GKRS showed long-term benefit, supporting its selective use and long-term surveillance beyond 10 years.